Showing results (1241-1250 of 1,520) with videos related to

Sort By:
Pageof 152
Nature Reviews. Cancer|January 26, 2007
Compressing drug development timelines in oncology using phase '0' trialsShivaani Kummar, Robert Kinders, Larry Rubinstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 1999
A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumorsJ L Grem, J M Sorensen, E Cullen, et al.
Cancer Research|October 7, 2004
Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastomaJun S Wei, Braden T Greer, Frank Westermann, et al.
Digital Health|October 3, 2024
Sociodemographic predictors of successful screening and subsequent randomization in a digital health hypertension interventionHailey N Miller, Sandy Askew, Miriam B Berger, et al.
Blood Advances|July 24, 2023
A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trialsSara K Silbert, Sanna Madan, Elizabeth M Holland, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|April 2, 2009
Complications related to endoscopic retrograde cholangiopancreatography: a comprehensive clinical reviewMatthew L Silviera, Mark J Seamon, Brian Porshinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2016
Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric SarcomasMelinda S Merchant, Donna Bernstein, Martha Amoako, et al.
The Journal of Thoracic and Cardiovascular Surgery|March 30, 2001
Minimally invasive versus sternotomy approaches for mitral reconstruction: comparison of intermediate-term resultsE A Grossi, A LaPietra, G H Ribakove, et al.
The Lancet. Oncology|February 14, 2012
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialRavi A Madan, Mahsa Mohebtash, Philip M Arlen, et al.
Journal of Clinical Pharmacology|August 28, 2015
Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancerAndrew K L Goey, Tristan M Sissung, Cody J Peer, et al.
Pageof 152